Clinical trial
Interleukin-2 in Treating Patients With Metastatic Melanoma
NCT00002845 · Blumenthal Cancer Center at Carolinas Medical Center, Other · Unknown status
Key facts
| NCT number | NCT00002845 |
|---|---|
| Title | Interleukin-2 in Treating Patients With Metastatic Melanoma |
| Official title | TREATMENT OF METASTATIC MELANOMA WITH RECOMBINANT INTERLEUKIN-2 |
| Lead sponsor | Blumenthal Cancer Center at Carolinas Medical Center, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | aldesleukin |
| Enrollment | 20 |
| Start date | Sep 1, 1995 |
| First posted | Aug 24, 2004 |
| Last update posted | Dec 19, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: